Craig-Hallum provides banking, research, institutional sales, and trading services. This description is self-described.

Craig-Hallum

Craig-Hallum Capital Group | 5,455 followers on LinkedIn. Employee-owned, idea-driven research, trading and investment banking firm.  | Since starting in 1997, we have kept our focus clear: help our clients achieve their goals. The success of our firm depends on our culture and our people. We believe we have some of the best at what they do and we’re committed to working hard and staying true to our business model.

Managing Director at Craig-Hallum Capital Group

Joseph Dews

George Sutton

Eric Stine

Chief Compliance Officer at Craig-Hallum Capital Group

Chris Jensen

Craig-Hallum Capital Group

Join us for Craig-Hallum’s first Nuclear Energy Revisited – Virtual Conference on Wednesday, December 11, 2024. Featuring 1x1 meetings with a range of public and private companies that participate in the nuclear supply chain from fuels to fission and fusion reactors. This conference will highlight key marketplace developments that are driving the nuclear renaissance as well as feature a “Nuclear Energy 101” Teach-in Fireside Chat with Eric Stine , Sr. Research Analyst. Please contact your Craig-Hallum representative to register.

Congratulations to our client Applied DNA Sciences, Inc. (APDN) on the success of its recent offering in October 2024 where Craig-Hallum served as sole placement agent. APDN is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (“DNA”) and ribonucleic acid (“RNA”).

Congratulations to our client Applied Digital Corp. (APLD) on the success of its recent offering in October 2024 where Craig-Hallum served as co-manager. APLD is a designer, developer, and operator of next-generation digital infrastructure across North America. They provide digital infrastructure solutions and cloud services to the rapidly growing industries of High-Performance Computing and Artificial Intelligence.

Congratulations to our Senior Research Analyst, Matt Hewitt, on hosting a successful turnout at the virtual Bioprocessing Conference held last week. The bioprocessing industry plays a crucial role in the development and commercialization of biologic drugs and cell and gene therapies. During the conference, our clients delved into how bioprocessing tools and services are driving innovation and transforming the pharmaceutical and biotechnology industries. With 10 companies hosting fireside chats and close to 90 1x1 meetings, our conferences continue to reflect our ongoing commitment to identify and introduce investment opportunities to our clients. Thank you to all our participants.

Congratulations to our client Orion Group Holdings, Inc. (ORN) on the success of its recent offering in September 2024 where Craig-Hallum served as sole book-running manager. ORN is a leading specialty construction company serving the infrastructure, industrial, and building sectors, providing services both on and off the water in the continental United States, Alaska, Hawaii, Canada and the Caribbean Basin through their marine segment and their concrete segment.

Congratulations to our client Zeta Global Holdings Corp. (ZETA) on the success of its recent offering in September 2024 where Craig-Hallum served as co-manager. Zeta is a leading omnichannel data-driven cloud platform that provides enterprises with consumer intelligence and marketing automation software.

Congratulations to our client Phathom Pharmaceuticals, Inc. (PHAT) on the success of its recent offering in August 2024 where Craig-Hallum served as co-lead manager. PHAT is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases.

Congratulations to our client Life Time Group Holdings, Inc. (LTH) on the success of its recent offering in August 2024 where Craig-Hallum served as co-manager. Life Time, the “Healthy Way of Life Company,” is a premier lifestyle and leisure brand offering premium health, fitness and wellness experiences to a community of more than 1.5 million individual members.

Congratulations to our client scPharmaceuticals Inc. (SCPH) on the success of its recent offering in August 2024 where Craig-Hallum served as co-manager. SCPH is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs.

Congratulations to our client Xtant Medical Holdings, Inc. (XTNT) on the success of its recent offering in August 2024 where Craig-Hallum served as sole placement agent. XTNT is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures.

Metric
Company Name	Craig-Hallum
Symbol
MSH ID	COM:CRAIG-HALLUM
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Investment Banking
Country	US
Stage
Employee Count
Website	craig-hallum.com
LinkedIn	craig-hallum-capital-group
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	21.59K
Web Traffic Growth	2.23
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CRAI

COM:CRAIG-HALLUM

Craig-Hallum

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue